Olpasiran leads to significant and sustained reduction in oxidized phospholipids on apolipoprotein B. HealthDay News — Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a ...
The RNA inhibitor olpasiran significantly reduces a type of “bad cholesterol” that’s associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...
An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 ...
Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...
Hosted on MSN1mon
Clinical trial finds RNA inhibitor effectively reduces 'bad cholesterol' in patients with cardiovascular diseaseThe study reported that higher doses of olpasiran lowered the type of cholesterol called lipoprotein(a) [Lp(a)] by more than 95% in participants with atherosclerotic cardiovascular disease ...
Hosted on MSN1mon
Olpasiran Leads to Significant Reduction in Oxidized PhospholipidsThe researchers found that the placebo-adjusted mean percentage change in OxPL on apoB (OxPL-apoB) concentration from baseline to week 36 was −51.6, −89.7, −92.3, and −93.7 percent for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback